Clinical Trial Opportunities
Be a part of the groundbreaking research currently being conducted at Sheppard Pratt.
Efficacy, Safety, and Tolerability of COMP360 in Participants with Treatment-Resistant Depression
This outpatient double blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of COMP360 (synthetic psilocybin) administered with psychological support in participants with treatment-resistant depression. The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week screening period.
Eligibility: We are currently seeking participants who meet the following criteria
• 18 years or older
• Meet diagnostic criteria for Major Depressive Disorder at screening, with symptoms that have been present for ≥ 4 weeks
o If single episode MDD, the episode duration be ≥3 months and ≤2 years at screening.
• Must have ≥ 2 failed antidepressant treatments in the current depressive episode
• At screening, agreement to discontinue all prohibited medications
• Must be able to accommodate multiple in-clinic visits in Towson, MD
PI: Scott Aaronson, MD
Sponsor: COMPASS Pathways
Interested in participating? Please complete this survey to get in touch with the IADT research team. Upon completion, the team will review your responses and may reach out to further explore your suitability for the trial.
Treatment-Resistant Depression and Chronic Suicidal Ideation
This study will evaluate the efficacy and safety of a single-open label dose of psilocybin administered under supportive conditions to adults with treatment-resistant depression and chronic suicidal ideation in improving depressive symptoms. The study lasts between 15-18 weeks.
Eligibility: We are currently seeking participants who meet the following criteria
• Between 18 and 65 years old at screening
• Meet diagnostic criteria for single-episode or recurrent Major Depressive Disorder
• Must have presence of suicidal thoughts with active ideation
• Must have failed ≥ 2 failed antidepressant treatments in the current episode
• Must be able to accommodate multiple in-clinic visits in Towson, MD
PI: Scott Aaronson, MD
Sponsor: COMPASS Pathways
Interested in participating? Please complete this survey to get in touch with the IADT research team. Upon completion, the team will review your responses and may reach out to further explore your suitability for the trial.
Bipolar Depression - A trial of an add-on probiotic to prevent relapse and improve the clinical course after hospitalization for bipolar depression
This study is seeking volunteers for a clinical trial that may help prevent readmission for an exacerbation of psychiatric symptoms. Participants take add-on probiotics or placebo for 24 weeks and are compensated for their time.
Probiotic supplements contain tiny healthy organisms similar to those found in breast milk, yogurt, and some other foods. They are thought to provide health benefits by improving digestion and modulating the immune response.
Eligibility
- Currently or recently admitted to an inpatient or day hospital program for symptoms of bipolar depression, and with a diagnosis of Bipolar I or II disorder
- 18 - 65 years old
- Available for follow-up phone calls weekly and in-person visits every four weeks at Sheppard Pratt's Towson campus during a 24-week treatment period
PI: Faith Dickerson, PhD, MPH
Founding source: Stanley Medical Research Institute
For further information please contact Emily Katsafanas at ekatsafanas@sheppardpratt.org.
Schizophrenia - A trial of an add-on synbiotic to reduce psychiatric symptoms
This study is seeking volunteers for a clinical trial that may help reduce psychiatric symptoms of schizophrenia or schizoaffective disorder.
Participants take an add-on synbiotic supplement or placebo for 14 weeks and are compensated for their time.
Synbiotic supplements contain probiotics which are tiny healthy organisms similar to those found in breast milk, yogurt, and some other foods, and a prebiotic which helps “good” bacteria to grow in the digestive tract. Probiotics and prebiotics are thought to provide health benefits by improving digestion and modulating the immune response.
Eligibility
- Currently receiving outpatient treatment with a diagnosis of Schizophrenia or Schizoaffective Disorder.
- Receiving the same dose of antipsychotic medication for at least 8 weeks
- 18 - 65 years old
- Available for in-person visits every two weeks during a 14-week treatment period
PI: Faith Dickerson, PhD, MPH
For further information please contact Emily Katsafanas at ekatsafanas@sheppardpratt.org.